Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Carcinoma, Hepatocellular 7Neoplasm Metastasis 4Liver Neoplasms 4Leiomyoma 3Uveal Melanoma 2Spinal Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pelvic Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Chylous Ascites 1Blood Loss, Surgical 1Abdominal Neoplasms 1

Interventions

Ipilimumab 16incomplete Freund's adjuvant 9Nivolumab 9sargramostim 6Temozolomide 6Dacarbazine 6montanide ISA 51 5MART-1 Antigen 5Blood Specimen Collection 5pembrolizumab 4Ranibizumab 4Melphalan 4Interleukin-2 4Carboplatin 4CTLA-4 Antigen 4Thalidomide 3Surveys and Questionnaires 3MAGEA3 protein, human 3Granulocyte-Macrophage Colony-Stimulating Factor 3AZD 6244 3sotrastaurin 2relatlimab 2gp100 Melanoma Antigen 2fludarabine phosphate 2fludarabine 2entinostat 2aflibercept 2Taxes 2Sunitinib 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Uveal Melanoma × Embolization, Therapeutic × Clear all
NCT00661622 2025-05-16

Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF

Thomas Jefferson University

Phase 2 Completed
53 enrolled 12 charts
Dermatologic

Uveal Melanoma

NCT03472586 2025-04-24

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Thomas Jefferson University

Phase 2 Completed
14 enrolled 8 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡